WAVEMAN · COMPANY

SPRO · Spero Therapeutics, Inc.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

SPRO

Name: Spero Therapeutics, Inc. (SPRO) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Spero Therapeutics, Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001701108

SEC FILINGS☆ WATCH

INSIDER NET · 180D

-$63.4K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+3292.5%

XBRL, annual

NET MARGIN

68.1%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$63.4K over 180 days

more than 57% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

40 funds added or opened last quarter

below 59% of Pharma & Biotech

REVENUE

+3292.5% year over year

more than 98% of Pharma & Biotech

MARGIN

68.1% net margin

more than 97% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

40 funds added or opened positions in the latest 13F quarter, of 62 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -40.5%

-40.5%12M

INSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows a net $63.4K sold by insiders over 180 days, 40 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Spero Therapeutics, Inc. insiders sold a net $63.4K of stock across 74 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

Rajavelu Esther

See Remarks

SELL

2026-05-04

25,240.0

$63.4K

Rajavelu Esther

See Remarks

SELL

2026-02-06

37,101.0

$87.6K

Rajavelu Esther

See Remarks

SELL

2026-02-06

50,816.0

$119.9K

Keutzer Timothy

Chief Operating Officer

SELL

2026-02-06

18,652.0

$44.0K

Keutzer Timothy

Chief Operating Officer

SELL

2026-02-04

3,471.0

$7.8K

74 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 69 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

GSK plc

9,190,606.0 sh

$20.3M

Pfizer Inc

2,362,348.0 sh

$5.3M

VANGUARD CAPITAL MANAGEMENT LLC

2,036,226.0 sh

$4.5M

RENAISSANCE TECHNOLOGIES LLC

947,904.0 sh

$2.1M

Alphabet Inc.

889,979.0 sh

$2.0M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Invesco NASDAQ Future Gen 200 ETF

$59.7K POSITION · AS OF 2026-02-28

0.4%

Ultra-Small Company Market Fund

$151.6K POSITION · AS OF 2026-03-31

0.1%

Omni Small-Cap Value Fund

$117.0K POSITION · AS OF 2026-03-31

0.0%

Small Cap Core Fund

$14.3K POSITION · AS OF 2026-03-31

0.0%

Victory Extended Market Index Fund

$11.7K POSITION · AS OF 2026-04-30

0.0%

VANGUARD EXTENDED MARKET INDEX FUND

$1.2M POSITION · AS OF 2026-03-31

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 7 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

0 ACTIVE

Phase 2

0 ACTIVE

Phase 3

0 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Government contracts

USASpending.gov · total award ceilings over the contract's life, including awards won through subsidiaries — not annual revenue

Department Of Health And Human Services

IGF::OT::IGF · 2018-07-12

$49.2M

Department Of Health And Human Services

TO ADVANCE CLINICAL AND NON-CLINICAL DEVELOPMENT OF AN ANTIBIOTIC CANDIDATE. · 2021-05-17

$10.5M

FEDERAL AWARDS ≥ $25M IN THE LAST 90 DAYS · MATCHED VIA SAM.GOV PARENT REGISTRY

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$12.6M	$371.0K	$933.0K	$2.5M
OPERATING INCOME	$6.3M	$-73.4M	$21.5M	$-42.2M
NET INCOME	$8.6M	$-68.6M	$22.8M	$-46.4M
EPS (DILUTED)	0.15	-1.27	0.43	-1.23
OPERATING CASH FLOW	$-12.6M	$-23.4M	$-33.0M	$-7.7M
CASH	$40.3M	$52.9M	$76.3M	$109.1M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE